A CD47 bsAb comprised of CD33 mAb gemtuzumab and CD47 mAb 11a1 called HMBD004 inhibited CD47‐SIRPα binding, thereby improving phagocytosis of HL60 AML cells and extending survival in a murine xenograft model. This evidence concerns the gene SIRPA and acute myeloid leukemia.